Olmesartan/amlodipine
Combination of | |
---|---|
Olmesartan | Angiotensin II antagonist |
Amlodipine | Calcium channel blocker |
Clinical data | |
Trade names | Azor |
AHFS/Drugs.com | entry |
Pregnancy category |
|
Legal status |
|
Routes of administration |
Oral |
Identifiers | |
ATC code | C09DB02 (WHO) |
The combination drug olmesartan/amlodipine (trade name Azor in the US) is an oral antihypertensive medication which combines two antihypertensive agents in a film-coated tablet. It contains amlodipine, a calcium channel blocker, and olmesartan medoxomil (trade name: Benicar), an angiotensin-2 receptor antagonist (ARB or A2A). The patent is held by Daiichi Sankyo Pharmaceuticals. Daiichi Sankyo filed a supplemental New Drug Application (sNDA) for Azor with the United States Food and Drug Administration on September 17, 2008.[1] Azor has been studied in clinical trials; one test showed it reduced blood pressure during a 24-hour period and was well tolerated.[2] Azor is available in different dose preparations: 5 mg/20 mg, 10 mg/20 mg,5 mg/40 mg and 10/40 mg's of amlodipine and olmesartan respectively.[3] One investigation (which included doctors employed by Daiichi Sankyo) concluded that "From a pharmacokinetic perspective, the 2 drugs (amlodipine and olmesartan) are well suited to coadministration in a fixed-dose combination."[4]
References
<templatestyles src="Asbox/styles.css"></templatestyles>
- Drugs that are a combination of chemicals
- Chemical articles without CAS Registry Number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- Calcium channel blockers
- Antihypertensive agents
- Combination drugs
- Pages with broken file links
- Antihypertensive agent stubs